<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling</title>
			</titleStmt>
			<publicationStmt>
				<publisher>S. Karger AG</publisher>
				<availability status="unknown"><p>Copyright S. Karger AG</p>
				</availability>
				<date type="published" when="2012-01-26">January 26, 2012</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">E</forename><surname>Westerweel</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jaap</forename><forename type="middle">A</forename><surname>Joles</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Krista</forename><surname>Den Ouden</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roel</forename><surname>Goldschmeding</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">University Medical Center Utrecht</orgName>
								<address>
									<settlement>Pathology, Utrecht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maarten</forename><forename type="middle">B</forename><surname>Rookmaaker</surname></persName>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marianne</forename><forename type="middle">C</forename><surname>Verhaar</surname></persName>
							<email>m.c.verhaar@umcutrecht.nl</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Departments of a Nephrology and Hypertension</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">University Medical Center Utrecht Department of Nephrology and Hypertension</orgName>
								<address>
									<addrLine>F03.227 Heidelberglaan 100</addrLine>
									<postCode>3584 CX</postCode>
									<settlement>Utrecht</settlement>
									<region>NL</region>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">ACE Inhibition in Anti-Thy1 Glomerulonephritis Limits Proteinuria but Does Not Improve Renal Function and Structural Remodeling</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Nephron Extra</title>
						<title level="j" type="abbrev">Nephron Extra</title>
						<idno type="eISSN">1664-5529</idno>
						<imprint>
							<publisher>S. Karger AG</publisher>
							<biblScope unit="volume">2</biblScope>
							<biblScope unit="issue">1</biblScope>
							<biblScope unit="page" from="9" to="16"/>
							<date type="published" when="2012-01-26">January 26, 2012</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1159/000335750</idno>
					<idno type="PMID">22479264</idno>
					<idno type="PMCID">PMC3318936</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-14T00:46+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>Background/Aims: ACE inhibitor (ACE-I) treatment effectively inhibits proteinuria and ameliorates the course of various renal diseases. In experimental glomerulonephritis, however, angiotensin II (AngII) infusion has also been shown to be renoprotective. We evaluated the long-term (28 days) course of anti-Thy1 glomerulonephritis in animals with suppressed AngII formation by ACE-I treatment. Methods: Brown Norway rats received perindopril (2.8 mg/kg/day, n = 12), dihydropyridine calcium-antagonist amlodipine (Ca-A; 13 mg/kg/day, n = 6) or were left untreated (n = 14). All animals were monitored for blood pressure, proteinuria, and creatinine clearance after anti-Thy1 injection. Renal histology was assessed at day 7 and 28. Results: Systolic blood pressure was equally reduced by ACE-I and Ca-A treatment. AngII suppression prevented development of proteinuria, but did not protect against glomerular microaneurysm formation or reduction in creatinine clearance. After resolution of the microaneurysms, animals with suppressed AngII production showed a modest increase in glomerulosclerosis and vasculopathic thickening of intrarenal vessels. Conclusions: In anti-Thy1 glomerulonephritis, suppression of AngII formation does not protect against the induction of glomerular damage and is associated</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>The anti-Thy1 glomerulonephritis model is characterized by marked transient proteinuria and involves both renal injury and repair. It therefore offers the potential to study various components of renal disease. Thy1 is expressed on glomerular mesangial cells. Binding of the anti-Thy1 antibody delivered by single injection results in complement-mediated mesangiolysis with secondary endothelial damage <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref> . The model is self-limiting and fully reversible in healthy animals, while uninephrectomized rats injected with anti-Thy1.1 antibody develop progressive glomerulosclerosis <ref type="bibr" target="#b2">[3]</ref> .</p><p>The potent antiproteinuric effects of ACE inhibitors (ACE-I) are well established. Angiotensin II (AngII) is a pathogenic factor in various renal diseases. However, AngII may also have renoprotective effects in early stages of kidney disease development. Stimulation of renal angiogenesis by AngII occurs during physiological postnatal kidney development <ref type="bibr" target="#b3">[4]</ref> and drives the accelerated glomerular recovery seen after infusion of AngII during early-phase anti-Thy1 glomerulonephritis <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref> . Consistently, glomerular endothelial cell proliferation after anti-Thy1 glomerulonephritis was inhibited with AngII receptor blockade <ref type="bibr" target="#b6">[7]</ref> . The attenuated glomerular injury with AngII infusion is in apparent contrast with previous studies in the anti-Thy1 model suggesting attenuation of renal damage by treatment with ACE-I or AngII receptor blocker <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref> . The latter studies reported improvement mainly in terms of reduced proteinuria and early reduction of matrix expansion. We hypothesized that the suppression of AngII formation would not improve late-stage renal function in anti-Thy1 glomerulonephritis despite possible antiproteinuric effects. Therefore, we evaluated the effect of ACE-I treatment using perindopril on proteinuria, creatinine clearance, induction of glomerular damage and renal histological recovery in nephritic rats. To dissociate direct effects of ACE-I treatment from those on blood pressure reduction, we also included nephritic rats treated with the dihydropyridine calcium-antagonist amlodipine (Ca-A) in our study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Animals</head><p>Male 11-week-old Brown Norway/RijHsd (BN) rats weighing 280-300 g (Harlan, Horst, The Netherlands) housed in a 12/12 h light/dark cycle and receiving food and acidified water ad libitum were used for all experiments. The Animal Ethics Committee of our institution approved all protocols.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Experimental Design</head><p>Anti-rat Thy1.1 monoclonal antibody (ER4, 1 mg/kg body weight) was injected intravenously on day 0 in all rats. Rats treated with ACE-I perindopril (gift from Servier; 33 mg/l in the drinking water, resulting in an average dose of 2.8 mg/kg body weight/day; n = 12) since day 3 before anti-Thy1 injection were compared to controls (n = 14) and rats treated with Ca-A (gift from Servier; 150 mg/l in the drinking water, resulting in an average dose of 13 mg/kg body weight/day; n = 6). Rats were placed in metabolic cages with free access to food and water at several time points to collect 24-hour urine samples. Systolic blood pressure was measured in conscious rats by tail-cuff sphygmomanometry (IITC, San Diego, Calif., USA). Rats were sacrificed at day 7 (n = 4 control vs. n = 6 ACE-I-treated animals) and day 28 (n = 10 control vs. n = 6 ACE-I-treated and n = 6 Ca-A-treated animals), and kidneys were excised after perfusion at 120 mm Hg with ice-cold 0.9% saline. Kidney specimens were transversely cut in 1-mm slices, fixed in 4% buffered formaldehyde and embedded in paraffin.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Measurements of Renal Function Parameters</head><p>Urinary protein concentration was determined by Bio-Rad Protein assay (Bio-Rad Laboratories GmbH, München, Germany) in 24-hour urine samples. Plasma and urinary creatinine levels were determined colorimetrically (Sigma Diagnostics Inc., St. Louis, Mo., USA). The creatinine clearance, calculated by the standard formula, was used as an estimate of glomerular filtration rate (GFR).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Renal Histology</head><p>Renal morphology was evaluated using Periodic Acid Schiff (PAS)-stained 5-m paraffin sections, based on at least 50 glomeruli per kidney section. The percentage of glomeruli containing microaneurysms was counted in sections from rats terminated at day 7. The Glomerular Sclerosis Index (GSI) was calculated as previously described <ref type="bibr" target="#b13">[14]</ref> in sections from rats terminated at day 28. For the GSI, glomeruli were scored based on the percentage of the glomerular area that was sclerotic (normal = 0, ! 25% = 1, 25-50% = 2, 50-75% = 3, 75-100% = 4). Renal artery wall thickness of the cortical intrarenal arteries in PAS-stained kidney sections was measured using AnalySIS 3.0 software (Soft Imaging Systems, Münster, Germany), based on lamina externa and interna diameters and using the average of at least five vessels per kidney section.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical Analysis</head><p>All values are expressed as mean 8 SEM. Data were analyzed using SPSS version 11.0 software. Differences between groups were analyzed using the Student t test, and one-or two-way ANOVA with Kruskal-Wallis post-hoc test if appropriate. A p value ! 0.05 was considered significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACE-I and Ca-A Lowered Systolic Blood Pressure</head><p>Baseline systolic blood pressure was 112 8 3 mm Hg. At the time of anti-Thy1 injection, systolic blood pressure was reduced by 19 8 2 mm Hg in ACE-I-treated rats (p ! 0.001) and by 22 8 3 mm Hg in Ca-A-treated rats (p = 0.001), and this level of blood pressure reduction was sustained. The difference in blood pressure reduction for Ca-A and ACE-I treatment was not significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACE-I, but Not Ca-A, Inhibited the Development of Proteinuria after Anti-Thy1 Injection</head><p>In control rats, induction of glomerulonephritis caused an increase in urinary protein excretion peaking at day 7 ( <ref type="figure" target="#fig_0">fig. 1</ref> ). ACE-I treatment significantly reduced the development of proteinuria and resulted in normalization of proteinuria at day 14 when proteinuria was still high in controls (p ! 0.01 for treatment interaction in two-way ANOVA for time and treatment interaction). Ca-A treatment did not affect the development of proteinuria ( <ref type="figure" target="#fig_0">fig. 1</ref> ).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACE-I Did Not Attenuate the Reduction of Creatinine Clearance after Anti-Thy1 Glomerulonephritis</head><p>Creatinine clearance was reduced at day 28 in all nephritic rats ( table 1 ). In perindopriltreated animals, creatinine clearance was not beneficially affected.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACE-I Does Not Prevent Microaneurysm Formation in Early-Phase Anti-Thy1 Glomerulonephritis</head><p>Consistent with previous reports <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b15">16]</ref> , injection of anti-Thy1 caused acute mesangiolysis, capillary ballooning and microaneurysm formation at day 7 ( <ref type="figure" target="#fig_1">fig. 2 )</ref>. ACE-I treatment did not affect the percentage of microaneurysmatic glomeruli (40 8 4 vs. 41 8 5% in controls; p = not significant) at that time point. At day 28, microaneurysms were only sporadically observed in sections from both treated and untreated nephritic animals.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACE-I Treatment Aggravated Adverse Fibrotic Remodelling during Late-Stage Anti-Thy1 Glomerulonephritis</head><p>At day 28, nearly all microaneurysms had resolved, but around one third of glomeruli showed segmental glomerular sclerosis ( <ref type="figure" target="#fig_1">fig. 2 )</ref>. At day 28, ACE-I-treated animals had a slightly higher average glomerulosclerosis score than controls, which was statistically significant (GSI 0.49 8 0.07 vs. 0.36 8 0.03, p ! 0.05; <ref type="figure" target="#fig_2">fig. 3</ref> ). To further evaluate possible adverse fibrotic remodeling, we assessed intrarenal intima-media thickness as this was pathologically increased with ACE inhibition in experimental kidney transplantation <ref type="bibr" target="#b16">[17]</ref> . Indeed also in our model, ACE-I treatment was associated with signs of renal artery vasculopathy, with   <ref type="figure" target="#fig_3">fig. 4</ref> ). GSI in Ca-A-treated animals did not differ from controls (0.39 8 0.06 vs. 0.36 8 0.03, p = not significant; <ref type="figure" target="#fig_2">fig. 3</ref> ), and cortical artery wall thickness was unchanged in untreated controls and Ca-A-treated animals at day 28 ( <ref type="figure" target="#fig_3">fig. 4 )</ref>.  In kidney sections of rats with late-phase anti-Thy1 glomerulonephritis, a proportion of glomeruli showed signs of segmental glomerulosclerosis, which was histologically quantified using the GSI (see Animals and Methods section for specification of the scoring procedure). The GSI was higher in ACE inhibitor perindopril-treated animals (ACE-I aThy1) than in untreated controls (CON aThy1). Treatment with calcium-antagonist amlodipine (Ca-A aThy1) did not affect the development of glomerulosclerosis. * p ! 0.05 compared to untreated controls.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>A single intravenous injection of anti-Thy1 antibody is known to cause reversible glomerulonephritis characterized by marked transient proteinuria and multiple stages of structural glomerular pathology. Here, we show that ACE-I treatment during anti-Thy1 glomerulonephritis effectively reduces the development of proteinuria, but does not protect against the induction of glomerular damage or decline in renal function. ACE-I treatment could not prevent glomerular microaneurysm formation and was even associated with a modest but statistically significant accentuation of glomerulosclerosis and vasculopathic thickening of intrarenal vessels. Our study indicates that the multiple pathophysiological components during the course of anti-Thy1 glomerulonephritis are differentially affected by the suppression of AngII formation.</p><p>We show a potent protective effect of ACE inhibition on the proteinuria occurring during the development of glomerular damage. Several previous studies have similarly shown a reduction in proteinuria during anti-Thy1 glomerulonephritis by treatment with ACE-I or AngII receptor blockers <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref> . Consistently, proteinuria tended to stay elevated for a longer period of time when rats with anti-Thy1 glomerulonephritis received AngII infusion <ref type="bibr" target="#b5">[6]</ref> . Proteinuria is a practical and powerful indicator of the course of renal disease <ref type="bibr" target="#b17">[18]</ref> . Preventing or reducing proteinuria by ACE-I is well-established and likely to make a major contribution to the beneficial effects of ACE-I on the course of renal disease. Proteinuria is thought to not only reflect renal damage, but also play a pathophysiological role in the progression of renal damage itself <ref type="bibr" target="#b18">[19]</ref> . Indeed, in the aforementioned studies of ACE inhibition in anti-Thy1 glomerulonephritis, early matrix remodelling was inhibited. In our study, glomerular microaneurysm formation was not reduced by ACE inhibition. As glomerular microaneurysm formation reflects the degree of endothelial damage, the antiproteinuric effects do not appear to be attributable to endothelial protection but may be mediated through another mechanism. Such a specific antiproteinuric effect of ACE-I treatment may be explained by direct effects on the selective properties of the glomerular membrane size <ref type="bibr" target="#b19">[20]</ref> independent of the effects on the glomerulonephritic disease process.</p><p>Our study shows that in anti-Thy1 glomerulonephritis, inhibition of AngII formation promoted late-stage adverse sclerotic remodelling in both the glomerulus and intrarenal vasculature. This is in line with previous reports indicating that AngII infusion accelerated glomerular endothelial recovery <ref type="bibr" target="#b5">[6]</ref> , reduced influx of inflammatory cells, reduced mesangial proliferation, and limited matrix production <ref type="bibr" target="#b4">[5]</ref> . Similar deterioration of renal function and aggravated graft vasculopathy was observed in association with ACE-I treatment in the Fisher-to-Lewis experimental rat model of chronic renal transplant failure, even though the development of proteinuria and glomerulosclerosis was prevented <ref type="bibr" target="#b16">[17]</ref> . Furthermore, in both healthy and adriamycin-induced proteinuric rats on a low-sodium diet, ACE-I treatment caused interstitial renal damage and vasculopathic hypertrophy of intrarenal arteries <ref type="bibr" target="#b20">[21]</ref> .</p><p>We did not observe any effect of dihydropyridine Ca-A treatment on the course of anti-Thy1 nephritis. Unlike ACE-I, Ca-A treatment did not adversely affect the disease course, despite giving comparable blood pressure reduction. Thus, the adverse effects observed with ACE-I treatment appear to be independent of the systemic blood pressure-reducing action. Nevertheless, we cannot exclude a role for altered renal blood flow and filtration pressure, which are affected differently by dihydropyridine Ca-A and ACE-I <ref type="bibr" target="#b21">[22]</ref> .</p><p>In conclusion, our study suggests that ACE inhibition is effective in reducing proteinuria, but does not beneficially affect other pathological components involved in anti-Thy1 glomerulonephritis. This is in line with the concept that AngII may have specific renoprotective effects <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24]</ref> . Also, these results suggest that in specific conditions, proteinuria may thus not be a reliable indicator of the course of renal disease treated with ACE inhibitors.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc>Development of proteinuria over the course of anti-Thy1 glomerulonephritis. Induction of anti-Thy1 glomerulonephritis caused a transient rise in proteinuria in untreated rats (CON aThy1), which was not affected by treatment with calcium-antagonist amlodipine (Ca-A aThy1), but nearly fully prevented by treatment with the ACE inhibitor perindopril (ACE-I aThy1). * p ! 0.05 compared to untreated controls.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc>Morphological features of the anti-Thy1 glomerulonephritis model. Injection of anti-Thy1 in untreated rats causes acute mesangiolysis and capillary ballooning, which is visible on PAS-stained sections at day 7 as microaneurysms have formed. At day 28, nearly all microaneurysms are resolved, but many glomeruli show segmental glomerular sclerosis.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc>Glomerulosclerosis during late-phase anti-Thy1 glomerulonephritis.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 4 .</head><label>4</label><figDesc>Renal artery vessel wall thickness. Compared to untreated rats (CON aThy1), treatment with ACE inhibitor perindopril (ACE-I aThy1) was associated with vasculopathic thickening of the blood vessels in the renal cortex. Calcium-antagonist amlodipine (Ca-A aThy1) did not affect intrarenal vessel morphology. * p ! 0.05 compared to untreated controls at the equal time point.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>B iochemical parameters of renal function</figDesc><table><row><cell></cell><cell>Non-nephritic</cell><cell cols="2">aThy-1-nephritic</cell><cell cols="2">aThy-1-nephritic +</cell><cell cols="2">aThy-1-nephritic +</cell></row><row><cell></cell><cell>controls</cell><cell>controls</cell><cell></cell><cell>perindopril</cell><cell></cell><cell>amlodipine</cell><cell></cell></row><row><cell></cell><cell></cell><cell>day 7</cell><cell>day 28</cell><cell>day 7</cell><cell>day 28</cell><cell>day 7</cell><cell>day 28</cell></row><row><cell>Plasma urea, mM</cell><cell>8 .881.0</cell><cell>10.480.9</cell><cell>8.980.4</cell><cell cols="2">16.580.8* , # 17.081.6* , #</cell><cell>8.580.4</cell><cell>7.880.4</cell></row><row><cell>Creatinine clearance</cell><cell>7.581.2</cell><cell>7.981.7</cell><cell>4.780.4*</cell><cell>5.980.4</cell><cell>4.180.5*</cell><cell>9.680.7</cell><cell>5.580.5</cell></row><row><cell>ml/min/kg BW</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Proteinuria, mg/24 h</cell><cell>13.180.5</cell><cell cols="4">68.5810.7* 20.683.2* 24.383.2* , # 11.081.1* , #</cell><cell cols="2">58.185.6* 15.580.9</cell></row><row><cell cols="8">* p &lt; 0.05 compared to non-nephritic controls; # p &lt; 0.05 compared to nephritic controls at the corresponding time point.</cell></row></table><note>a significantly increased wall thickness of the cortical arteries at day 28 (intima-media sur- face area 4,046 8 419 vs. 2,689 8 195 m 2 , p ! 0.05;</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Nephron Extra 2012;2:9-16</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p>This work was supported by the Dutch Kidney Foundation (grant PC127) and the Netherlands Organization for Scientific Research (NWO VENI grant 016.036.041 and VIDI grant 917.96.359).</p><p>The technical assistance of Paula Martens, Ria de Winter, and Nel Willekes is gratefully acknowledged.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">M</forename><surname>Bagchus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">J</forename><surname>Hoedemaeker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Rozing</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">W</forename><surname>Bakker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="680" to="687" />
			<date type="published" when="1986" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Iruela-Arispe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gordon</forename><forename type="middle">K</forename><surname>Hugo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Duijvestijn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Claffey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">P</forename><surname>Reilly</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Couser</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">G</forename><surname>Alpers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">E</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="1715" to="1727" />
			<date type="published" when="1995" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Impairment of vascular regeneration precedes progressive glomerulosclerosis in anti-Thy 1 glomerulonephritis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoko</forename><surname>Wada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tetsuo</forename><surname>Morioka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yukiko</forename><surname>Oyanagi-Tanaka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yasuhito</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fumitake</forename><surname>Gejyo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masaaki</forename><surname>Arakawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takashi</forename><surname>Oite</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1523-1755.2002.00137.x</idno>
		<idno type="PMID">11849383</idno>
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="432" to="443" />
			<date type="published" when="2002-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Angiotensin II Promotes Development of the Renal Microcirculation through AT1 Receptors</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Madsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Marcussen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pedersen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kjaersgaard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Facemire</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">M</forename><surname>Coffman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Jensen</surname></persName>
		</author>
		<idno type="DOI">10.1681/asn.2009010045</idno>
		<idno type="PMID">20056745</idno>
		<idno type="PMCID">PMC2831863</idno>
		<ptr type="open-access" target="https://jasn.asnjournals.org/content/21/3/448.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of the American Society of Nephrology</title>
		<title level="j" type="abbrev">Journal of the American Society of Nephrology</title>
		<idno type="ISSN">1046-6673</idno>
		<idno type="ISSNe">1533-3450</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="448" to="459" />
			<date type="published" when="2010-01-07" />
			<publisher>American Society of Nephrology (ASN)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Angiotensin II infusion ameliorates the early phase of a mesangioproliferative glomerulonephritis11See Editorial by de Zeeuw, p. 1176.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ulrich</forename><forename type="middle">O</forename><surname>Wenzel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Friedrich</forename><surname>Thaiss</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Udo</forename><surname>Helmchen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rolf</forename><forename type="middle">A K</forename><surname>Stahl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gunter</forename><surname>Wolf</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1523-1755.2002.00192.x</idno>
		<idno type="PMID">11849457</idno>
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1020" to="1029" />
			<date type="published" when="2002-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Infusion of angiotensin II reduces loss of glomerular capillary area in the early phase of anti-Thy-1.1 nephritis possibly via regulating angiogenesis-associated factors</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuki</forename><surname>Takazawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yohei</forename><surname>Maeshima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroyuki</forename><surname>Kitayama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshihiko</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiroshi</forename><surname>Kawachi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fujio</forename><surname>Shimizu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hideki</forename><surname>Matsui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hitoshi</forename><surname>Sugiyama</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yasushi</forename><surname>Yamasaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hirofumi</forename><surname>Makino</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1523-1755.2005.00449.x</idno>
		<idno type="PMID">16014048</idno>
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="704" to="722" />
			<date type="published" when="2005-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Effects and mechanisms of angiotensin II receptor blockade with telmisartan in a normotensive model of mesangioproliferative nephritis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luigi</forename><surname>Villa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><surname>Boor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrzej</forename><surname>Konieczny</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Uta</forename><surname>Kunter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Claudia</forename><forename type="middle">R C</forename><surname>Van Roeyen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bernd</forename><surname>Denecke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lin</forename><surname>Gan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">B</forename><surname>Kupper</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kurt</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Frank</forename><surname>Eitner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tammo</forename><surname>Ostendorf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jürgen</forename><surname>Floege</surname></persName>
		</author>
		<idno type="DOI">10.1093/ndt/gfr096</idno>
		<idno type="PMID">21414972</idno>
		<ptr type="open-access" target="https://academic.oup.com/ndt/article-pdf/26/10/3131/17171565/gfr096.pdf" />
	</analytic>
	<monogr>
		<title level="j">Nephrology Dialysis Transplantation</title>
		<idno type="ISSN">0931-0509</idno>
		<idno type="ISSNe">1460-2385</idno>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="3131" to="3143" />
			<date type="published" when="2011-03-17" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Zoja</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Abbate</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Corna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Capitanio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Donadelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Bruzzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Oldroyd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Benigni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Remuzzi</surname></persName>
		</author>
		<idno type="DOI">10.1053/ajkd.1998.v31.pm9506682</idno>
		<idno type="PMID">9506682</idno>
		<idno type="PII">S0272-6386(98)00068-7</idno>
		<idno type="ark">ark:/67375/6H6-J98KPZPG-5</idno>
		<idno type="istexId">E9CABFD120DA5FE6DE534078BDC999E06BB8A9CE</idno>
	</analytic>
	<monogr>
		<title level="j">American Journal of Kidney Diseases</title>
		<title level="j" type="abbrev">American Journal of Kidney Diseases</title>
		<idno type="ISSN">0272-6386</idno>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="453" to="463" />
			<date type="published" when="1998-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Targeting TGF- overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">A</forename><surname>Border</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">A</forename><surname>Noble</surname></persName>
		</author>
		<idno type="DOI">10.1093/ndt/14.suppl_4.22</idno>
		<idno type="PMID">10463199</idno>
		<ptr type="open-access" target="https://academic.oup.com/ndt/article-pdf/14/suppl_4/22/13067137/10463199.pdf" />
	</analytic>
	<monogr>
		<title level="j">Nephrology Dialysis Transplantation</title>
		<title level="j" type="abbrev">Nephrology Dialysis Transplantation</title>
		<idno type="ISSN">0931-0509</idno>
		<idno type="ISSNe">1460-2385</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">suppl 4</biblScope>
			<biblScope unit="page" from="22" to="23" />
			<date type="published" when="1999-08-01" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harm</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wayne</forename><forename type="middle">A</forename><surname>Border</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nancy</forename><forename type="middle">A</forename><surname>Noble</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1523-1755.2000.00994.x</idno>
		<idno type="PMID">10760085</idno>
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1493" to="1501" />
			<date type="published" when="2000-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Angiotensin-converting enzyme inhibition but not β-adrenergic blockade limits transforming growth factor-β overexpression in acute normotensive anti-thy1 glomerulonephritis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harm</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthias</forename><surname>Rückert</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jens</forename><surname>Gaedeke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lutz</forename><surname>Liefeldt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Markus</forename><surname>Ketteler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arya</forename><forename type="middle">M</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Null-</forename><forename type="middle">H</forename><surname>Neumayer</surname></persName>
		</author>
		<idno type="DOI">10.1097/00004872-200304000-00021</idno>
		<idno type="PMID">12658024</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Hypertension</title>
		<title level="j" type="abbrev">Journal of Hypertension</title>
		<idno type="ISSN">0263-6352</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="771" to="780" />
			<date type="published" when="2003-04" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Platelet inhibition limits TGF-β overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harm</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ralph</forename><surname>Eisenberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ute</forename><surname>Daig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lutz</forename><surname>Liefeldt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ralf</forename><surname>Westenfeld</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jens</forename><surname>Gaedeke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephanie</forename><surname>Krämer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Null-</forename><forename type="middle">H</forename><surname>Neumayer</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1523-1755.2004.00630.x</idno>
		<idno type="PMID">15149337</idno>
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2238" to="2248" />
			<date type="published" when="2004-06" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Angiotensin II Receptor Blockade Ameliorates Mesangioproliferative Glomerulonephritis in Rats through Suppression of CTGF and PAI-1, Independently of the Coagulation System</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ning</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shinya</forename><surname>Shimizu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toshiko</forename><surname>Ito-Ihara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kuniaki</forename><surname>Takagi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Toru</forename><surname>Kita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Takahiko</forename><surname>Ono</surname></persName>
		</author>
		<idno type="DOI">10.1159/000098321</idno>
		<idno type="PMID">17199095</idno>
	</analytic>
	<monogr>
		<title level="j">Nephron Experimental Nephrology</title>
		<title level="j" type="abbrev">Nephron Exp Nephrol</title>
		<idno type="ISSN">1660-2129</idno>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="e65" to="e74" />
			<date type="published" when="2007" />
			<publisher>S. Karger AG</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">El Nahas AM: The role of growth hormone and insulin-like growth factor-I in experimental renal growth and scarring</title>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="677" to="679" />
			<date type="published" when="1991" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">M</forename><surname>Bagchus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">J</forename><surname>Hoedemaeker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Rozing</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">W</forename><surname>Bakker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="680" to="687" />
			<date type="published" when="1986" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Bone-Marrow-Derived Cells Contribute to Glomerular Endothelial Repair in Experimental Glomerulonephritis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maarten</forename><forename type="middle">B</forename><surname>Rookmaaker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anke</forename><forename type="middle">M</forename><surname>Smits</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Herman</forename><surname>Tolboom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karin</forename><surname>Van 't Wout</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anton</forename><forename type="middle">C</forename><surname>Martens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roel</forename><surname>Goldschmeding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jaap</forename><forename type="middle">A</forename><surname>Joles</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anton</forename><forename type="middle">Jan</forename><surname>Van Zonneveld</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Herman-Joseph</forename><surname>Gröne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ton</forename><forename type="middle">J</forename><surname>Rabelink</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marianne</forename><forename type="middle">C</forename><surname>Verhaar</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0002-9440(10)63683-8</idno>
		<idno type="PMID">12875975</idno>
		<idno type="PMCID">PMC1868209</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc1868209?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">The American Journal of Pathology</title>
		<title level="j" type="abbrev">The American Journal of Pathology</title>
		<idno type="ISSN">0002-9440</idno>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="553" to="562" />
			<date type="published" when="2003-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Annemieke</forename><surname>Smit-Van Oosten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gerjan</forename><surname>Navis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Coen</forename><forename type="middle">A</forename><surname>Stegeman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jaap</forename><forename type="middle">A</forename><surname>Joles</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pieter</forename><forename type="middle">A</forename><surname>Klok</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Folkert</forename><surname>Kuipers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anton</forename><forename type="middle">T M G</forename><surname>Tiebosch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harry</forename><surname>Van Goor</surname></persName>
		</author>
		<idno type="DOI">10.1002/1096-9896(200105)194:1&lt;122::aid-path859&gt;3.0.co;2-t</idno>
		<idno type="PMID">11329151</idno>
		<idno type="ark">ark:/67375/WNG-0DZXCS2F-8</idno>
		<idno type="istexId">B2C7E973EDB68BCF6D94FD25048C51F959AC21E8</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Pathology</title>
		<title level="j" type="abbrev">J. Pathol.</title>
		<idno type="ISSN">0022-3417</idno>
		<idno type="ISSNe">1096-9896</idno>
		<imprint>
			<biblScope unit="volume">194</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="122" to="129" />
			<date type="published" when="2001" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Update on microalbuminuria as a biomarker in renal and cardiovascular disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lambers</forename><surname>Heerspink</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">J</forename><surname>Brinkman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">W</forename><surname>Bakker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Gansevoort</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">T</forename><surname>De Zeeuw</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Nephrol Hypertens</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="631" to="636" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Progression, remission, regression of chronic renal diseases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Piero</forename><surname>Ruggenenti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arrigo</forename><surname>Schieppati</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giuseppe</forename><surname>Remuzzi</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0140-6736(00)04728-0</idno>
		<idno type="PMID">11377666</idno>
		<idno type="PII">S0140-6736(00)04728-0</idno>
		<idno type="ark">ark:/67375/6H6-DKQGQFJF-H</idno>
		<idno type="istexId">D568FC972EC78775733762D2FD001732A6A06322</idno>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<title level="j" type="abbrev">The Lancet</title>
		<idno type="ISSN">0140-6736</idno>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="issue">9268</biblScope>
			<biblScope unit="page" from="1601" to="1608" />
			<date type="published" when="2001-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Remuzzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Puntorieri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Battaglia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Bertani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Remuzzi</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci114470</idno>
		<idno type="PMID">1688888</idno>
		<idno type="PMCID">PMC296456</idno>
		<ptr type="open-access" target="http://www.jci.org/articles/view/114470/files/pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Investigation</title>
		<title level="j" type="abbrev">J. Clin. Invest.</title>
		<idno type="ISSN">0021-9738</idno>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="541" to="549" />
			<date type="published" when="1990-02-01" />
			<publisher>American Society for Clinical Investigation</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Hamming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Navis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mja</forename><surname>Kocks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Van Goor</surname></persName>
		</author>
		<idno type="DOI">10.1002/path.1956</idno>
		<idno type="PMID">16532430</idno>
		<idno type="ark">ark:/67375/WNG-Z54T3XXH-Q</idno>
		<idno type="istexId">1600B203E7588F7A7B1C3082EE69836F0BE365AA</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Pathology</title>
		<title level="j" type="abbrev">J. Pathol.</title>
		<idno type="ISSN">0022-3417</idno>
		<idno type="ISSNe">1096-9896</idno>
		<imprint>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="129" to="139" />
			<date type="published" when="2006" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Antihypertensive Therapy and Progression of Diabetic Renal Disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Hoelscher</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">George</forename><surname>Bakris</surname></persName>
		</author>
		<idno type="DOI">10.1097/00005344-199423001-00008</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Cardiovascular Pharmacology</title>
		<title level="j" type="abbrev">Journal of Cardiovascular Pharmacology</title>
		<idno type="ISSN">0160-2446</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">Supplement 1</biblScope>
			<biblScope unit="page" from="S34" to="S38" />
			<date type="published" when="1994" />
			<publisher>Ovid Technologies (Wolters Kluwer Health)</publisher>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Can angiotensin II be used for renoprotection?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dick</forename><surname>De Zeeuw</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1523-1755.2002.00239.x</idno>
		<idno type="PMID">11849474</idno>
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1176" to="1177" />
			<date type="published" when="2002-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">ACE inhibition and glomerular repair: restructuring or regeneration?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Joles</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Braam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>Verhaar</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.ki.5000237</idno>
		<idno type="PMID">16609678</idno>
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1105" to="1107" />
			<date type="published" when="2006-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
